← All trials
NCT03703388
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2019
- Primary completion
- Jan 14, 2020
- Completion date
- Jul 15, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, Los AngelesLead sponsor
- Charles Drew UniversityCollaborator
- Charles Drew UniversityOverall official - principal investigator
- Charles Drew UniversityOfficial
- University of California, Los AngelesOfficial
- University of California, Los AngelesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.